Coya Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| GOLDSTEIN DOV A MD | — | Option Exercise | 17,557 | $1.09 | $19,137 | 27,557 | Aug 18, 2025 |
| SNYDER DAVID S | Chief Financial Officer | Purchase | 1,800 | $7.19 | $12,942 | 8,800 | Nov 14, 2024 |
| Swaminathan Arun | Chief Executive Officer | Purchase | 5,000 | $7.36 | $36,800 | 10,000 | Nov 13, 2024 |
| Grossman Fred | Chief Medical Officer | Purchase | 2,710 | $7.37 | $19,973 | 2,710 | Nov 11, 2024 |
| Swaminathan Arun | Chief Executive Officer | Purchase | 5,000 | $7.34 | $36,700 | 5,000 | Nov 11, 2024 |
| Lee Ann | — | Purchase | 1,000 | $3.62 | $3,620 | 17,479 | Aug 22, 2023 |
| Berman Howard | Chief Executive Officer | Purchase | 10,000 | — | — | 10,000 | Jan 3, 2023 |
| Lee Ann | — | C | 6,479 | $4.00 | $25,916 | 16,479 | Jan 3, 2023 |
| Hepner Adrian | Chief Medical Officer | Purchase | 10,000 | — | — | 10,000 | Jan 3, 2023 |
| Garren Hideki | — | Purchase | 2,000 | — | — | 2,000 | Jan 3, 2023 |
| SNYDER DAVID S | Chief Financial Officer | Purchase | 7,000 | — | — | 7,000 | Jan 3, 2023 |
| Villalobos Anabella | — | Purchase | 10,000 | — | — | 10,000 | Jan 3, 2023 |
| GOLDSTEIN DOV A MD | — | Purchase | 10,000 | — | — | 10,000 | Jan 3, 2023 |